LAAO Pay Cut Sparks Card Group Opposition
CMS Cuts Reimbursement for Watchman and Other LAA Closure Devices, Sparking Debate
Table of Contents
The Centers for Medicare & Medicaid Services (CMS) has significantly reduced reimbursement for left atrial appendage (LAA) closure devices like the Watchman, a move that’s ignited controversy among cardiologists. The cuts,impacting reimbursement rates by as much as 50% in certain specific cases,are prompting concerns about patient access and the future of this increasingly popular choice to long-term oral anticoagulation for stroke prevention in atrial fibrillation (AFib).
The CMS Decision and Its Impact
CMS finalized its decision in early March, reducing payments for LAA closure procedures performed in outpatient settings. The agency cited a need to align reimbursement with the cost of the procedure and a desire to encourage the use of oral anticoagulants as a first-line therapy for stroke prevention in AFib patients.
The cuts are ample. Previously, hospitals received approximately $17,000 for the procedure; now, reimbursement is closer to $8,500. This financial strain is leading some hospitals to reconsider offering the procedure, potentially limiting access for eligible patients.
“The CMS cuts to such device reimbursements are significant and threaten patient safety and access to care,” said Muhammad Bilal Munir, MD, a professor of medicine in the Division of Cardiovascular Medicine at the University of California davis School of Medicine, Sacramento.
LAA Closure: An Alternative to Anticoagulation
LAA closure devices, such as the watchman, are implanted in the left atrial appendage – a small pouch in the heart were blood can pool and clot, increasing stroke risk in AFib patients. the device permanently seals off the appendage, preventing clots from escaping and traveling to the brain.
Oral anticoagulants, like warfarin and direct oral anticoagulants (DOACs), are the standard of care for stroke prevention in AFib. However, they come with a significant risk of bleeding, a major deterrent for many patients. LAA closure offers a potential alternative, eliminating the need for long-term medication and its associated bleeding risk.
“Oral anticoagulants are recommended as a first-line approach in lowering stroke risk in eligible patients with AFib,” Dr. Munir explained. “However, studies have shown significant underutilization of these drugs in real-world practice due to a multitude of factors. The LAAO devices were designed to address these unmet clinical needs.”
Benefits and Risks of LAA Closure
While LAA closure avoids the bleeding risks associated with anticoagulants, it’s not without its own potential complications. These include:
Leaks: Blood flow around the device.
bleeding Complications: Related to the implantation procedure itself.
Blood Clots: Formation on the device.
Systemic Embolization: Clots traveling to other parts of the body.
Stroke: Though the goal is prevention, stroke remains a potential risk.
The earlier generation of Watchman devices had a higher rate of complications, particularly related to leaks. However, Dr. Munir notes that improvements in device design have significantly reduced these risks.
The Controversy: Is LAA Closure Overused?
The efficacy and appropriate use of LAA closure devices are subjects of ongoing debate within the cardiology community. Some physicians, like John Tamola, MD, beleive the procedures are often performed unnecessarily and may even be harmful.
“Since I strongly believe there is little to no benefit for these procedures – perhaps even a net harm – I consider this a positive,” Dr. Tamola said, referring to the CMS cuts. He points to concerns about the PROTECT AF trial, which initially supported the Watchman, being rejected by the FDA due to internal validity issues. “No clear data exist comparing LAAO to direct oral anticoagulants or no anticoagulants,” he argues.
Anthony Pearson,MD,of The Skeptical Cardiologist*,echoes this sentiment,emphasizing the need for patients to have a thorough understanding of the risks and benefits before undergoing the procedure. he warns that some patients are convinced to pursue LAA closure without fully appreciating the potential for device-related thrombus.
Ongoing Research and the Future of LAA Closure
Despite the controversy, research continues to evaluate the role of LAA closure in stroke prevention. The Champion of trial, comparing LAA closure with direct-acting oral anticoagulants, is currently underway and aims to provide more definitive data on the efficacy and safety of these devices.
the results of this trial will be crucial in shaping future clinical guidelines and influencing CMS reimbursement